The results show increased expression of chemokine transcripts, IFNγ-related genes, higher infiltration of immune cells, and increased diversity of TCR clones among tumor-infiltrating lymphocytes, supporting an immunomodulatory effect of the ICIs therapy. This evidence concerns the gene IFNG and neoplasm.